ENG  Vol.5 No.10 B , October 2013
The Phenotypic Conversion of Macrophage Detected by FACS in EAE Mice Treated with or without Fasudil
Abstract: We studied the changes of macrophage populations in splenic mononuclear cells of experimental autoimmune ence-phalomyelitis (EAE) mice treated with or without Fasudil. Phenotypic analysis using flow cytometry showed that the levels of TLR4, CD11c and CD40 which represent the type 1 macrophage, were depressed in Fasudil-treated mice. Incontrast, it was observed the expressions of CD200 and CD14 which typify the type 2 macrophage were elevated in Fasudil-treated mice as compared to EAE mice. And we also found that Fasudil at dose of 40 mg/kg alleviated the se-verity of symptom in EAE mice. Based on the evidence that M1 macrophages are neurotoxic and M2 macrophages promote a regenerative growth, indicating that polarization and shifting of macrophages into M2 cells may also play key roles in treatment of EAE.
Cite this paper: Liu, C. , Xie, Y. , Li, Y. , Yu, J. , Feng, L. , Hou, S. , Zhang, H. , Ma, C. and Xiao, B. (2013) The Phenotypic Conversion of Macrophage Detected by FACS in EAE Mice Treated with or without Fasudil. Engineering, 5, 491-495. doi: 10.4236/eng.2013.510B101.

[1]   E. M. Frohman, M. K. Racke and C. S. Raine, “Multiple Sclerosis—The Plaque and Its Pathogenesis,” The New England Journal of Medicine, Vol. 254, 2006, pp. 942- 955.

[2]   R. J. Winquist, A. Kwong, R. Ramachandran and J. Jain, “The Complex Etiology of Multiple Sclerosis,” Biochemical Pharmacology, Vol. 74, 2007, pp. 1321-1329.

[3]   O. Neuhaus, O. Stüve, S. S. Zamvil and H. P. Hartung, “Are Statins a Treatment Option for Multiple Sclerosis?” The Lancet Neurology, Vol. 3, 2004, pp. 369-371.

[4]   X. Sun, M. Minohara, H. Kikuchi, T. Ishizu, M. Tanaka and H. Piao, et al., “The Selective Rho-Kinase Inhibitor Fasudil Is Protective and Therapeutic in Experimental Autoimmune Encephalomyelitis,” Journal of Neuroimmunology, Vol. 180, 2006, pp. 126-134.

[5]   Y. Gernez, L. A. Herzenberg, L. A. Herzenberg and R. Tirouvanziam, “Phospho-FACS: A Powerful Tool for Exploring Intracellular Transduction Cascades,” Revue des Maladies Respiratoires, Vol. 24, 2007, pp. 955-964.

[6]   T. W. Tung, K. Heydary, R. Tirouvanziam, B. Sahaf, D. R. Parks and L. A. Herzenberg, “Modern Flow Cytometry: A Practical Approach,” Clinics in Laboratory Medicine, Vol. 27, 2007, pp. 453-468.

[7]   A. A. Pineda, M. Minohara, N. Kawamura, T. Matsushita, R. Yamasaki, X. Sun, et al., “Preventive and Therapeutic Effects of the Selective Rho-Kinase Inhibitor Fasudil on Experimental Autoimmune Neuritis,” Journal of the Neurological Sciences, Vol. 306, 2011, pp. 115-120.

[8]   E. N. Benveniste, V. T. Nquyen and D. R. Wesemann, “Molecular Regulation of CD40 Gene Expression in Macrophages and Microglia,” Brain, Behavior, and Immunity, Vol. 18, 2004, pp. 7-12.

[9]   N. A. Wolf, T. K. Amouzeqar and R. H. Swanborq, “Synergistic Interaction between Toll-Like Receptor Agonists Is Required for Induction of Experimental Autoimmune Encephalomyelitis in Lewis Rats,” Journal of Neuroimmunology, Vol. 185, 2007, pp. 115-122.

[10]   S. Sinha, L. Miller, S. Subramanian, O. J. McCarty, T. Proctor, R. Meza-Romero, et al., “Binding of Recombinant T Cell Receptor Ligands (RTL) to Antigen Presenting Cells Prevents Upregulation of CD11b and Inhibits T Cell Activation and Transfer of Experimental Autoimmune Encephalomyelitis,” Journal of Neuroimmunology, Vol. 225, 2010, pp. 52-61.

[11]   S. G. Meuth, O. J. Simon, A. Grimm, N. Melzer, A. M. Herrmann, P. Spitzer, et al., “CNS Inflammation and Neuronal Degeneration Is Aggravated by Impaired CD200- CD200R-Mediated Macrophage Silencing,” Journal of Neuroimmunology, Vol. 194, 2008, pp. 62-69.